Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02801084
Other study ID # 2015-002-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2016
Est. completion date October 19, 2017

Study information

Verified date October 2020
Source Laureate Institute for Brain Research, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study proposed in this protocol aims to document the physiological, subjective, behavioral, and neural effects of reduced environmental stimulation (floating) in patients with current or prior anorexia nervosa The primary aim of this study is to determine the safety of this intervention. Secondary aims including determining whether floating has an impact on symptom reports such as those related to anxiety and eating disorders.


Description:

Floating creates an environment with minimal visual, auditory, tactile, proprioceptive, and thermal input to the brain. The float rooms used in this study are both lightproof, and thus completely dark when the entry door is sealed and the lights are turned off, reducing all visual input to the brain. Each float room was constructed with thick soundproof walls, restricting most outside noises from entering the room, thereby reducing auditory input to the brain. A high concentration Epsom salt water solution allows individuals to effortlessly float on their back while remaining completely still, reducing both proprioceptive and tactile input to the brain. The temperature of the water is calibrated to the temperature of the skin (~94° F) and the temperature of the air is calibrated to the temperature of the water, making it difficult to discern the boundary between air and water, thus reducing thermal input to the brain while minimizing the need for thermoregulation of the skin. While both float pools dramatically reduce external sensory information, it is important to note that participants are in full control over the experience. For example, participants can enter and exit the float pool whenever they choose. Each float pool also contains a blue LED light that can be turned on and off via an air-coupled light switch in the pool. Both float rooms contain a shower for cleaning before and after floating. In a prior study the investigators have found that healthy participants found the pool condition to be relaxing and stress relieving. The current study aims to determine the safety of floating with a clinical population, specifically individuals with a history of eating disorder who are of normal weight.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date October 19, 2017
Est. primary completion date October 19, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Current or prior diagnosis of anorexia nervosa (AN) 2. All AN participants must be weight-restored prior to their participation, defined as having a Body Mass Index (BMI) > 17.5 Exclusion Criteria: 1. Any of the following DSM-V disorders: 1. Schizophrenia Spectrum and Other Psychotic Disorders 2. Bipolar and Related Disorders 2. Currently being treated for their psychiatric condition as an inpatient. 3. Active suicidal ideation with intent or plan (as determined by a psychiatrist or clinical psychologist for all participants who report an IDAS-II suicide score > 10). 4. Morbid obesity (BMI > 40) or underweight (BMI < 17.5). 5. Orthostatic hypotension (defined as a drop of =20 mm Hg in systolic blood pressure or a drop of =10 mm Hg in diastolic blood pressure when measured shortly after transitioning from lying down to standing). 6. Certain drugs or medications consumed within the past week including any psychoactive drugs (e.g., MDMA, LSD, psilocybin, peyote, phencyclidine, ketamine), magnesium supplements (greater than 150mg) or milk of magnesia. Any antihistamine that causes drowsiness (e.g., Benadryl) or any alcohol consumed within the past 12 hours. Caffeine or nicotine consumed within the past 3 hours. For all other medications, participants must be stably medicated prior to participation (defined as having taken the medication for 6 weeks or longer). 7. History of unstable liver or renal insufficiency; glaucoma; diabetes; significant and unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic disturbance. 8. Pregnancy as detected by a urine test. 9. Failure to adhere to "Pre-float checklist". 10. Non-correctable vision or hearing problems.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Reduced environmental stimulation
Participants will complete one arm involving four sequential float sessions. Float 1: chair float. Participants will first float in a comfortable chair in the supine position, for up to 90 minutes. The chair is in a room with sound and light attenuation. Orthostatic blood pressure (BP) will be measured before and after each float. Anxiety and body image will be measured afterwards. Float 2: open pool float. Participants will float for up to 90 minutes in an open pool (8 foot diameter, no enclosure). Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards. Floats 3 & 4: domed pool float. Participants will float for up to 90 minutes in a domed pool the same size as the open pool, with an enclosure wall and 8 foot tall ceiling. Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards. Each float will occur approximately 1 to 7 days apart.

Locations

Country Name City State
United States Laureate Institute for Brain Research Tulsa Oklahoma

Sponsors (1)

Lead Sponsor Collaborator
Laureate Institute for Brain Research, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Khalsa SS, Moseman SE, Yeh HW, Upshaw V, Persac B, Breese E, Lapidus RC, Chappelle S, Paulus MP, Feinstein JS. Reduced Environmental Stimulation in Anorexia Nervosa: An Early-Phase Clinical Trial. Front Psychol. 2020 Oct 6;11:567499. doi: 10.3389/fpsyg.20 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Orthostatic blood pressure Defined as a drop of =20 mm Hg in systolic blood pressure or a drop of =10 mm Hg in diastolic blood pressure when measured shortly after transitioning from lying down to standing. Immediately before and after each float session for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration
Secondary Self-ratings of changes in emotional experience Measured via self-report measure (Positive and Negative Affect Schedule X) Immediately before and after each float session for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration
Secondary Self-ratings of changes in physical experience Interoceptive and exteroceptive sensations, measured via visual analogue scale (e.g., 0 to 100) Immediately before and after each float session for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration
Secondary Body image Measured via Photographic Figure Rating Scale, Body Appreciation Scale, Body Image States Scale, Body Shape Questionnaire, visual analogue scale (e.g., 0 to 10). Obtained at baseline and immediately after each float session for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration
Secondary EEG changes during the float experience May be measured during the first, second, and fourth float. During the first, second, and fourth float for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration
Secondary Heart rate variability during the float experience Measured during the first, second, and fourth float. Obtained at baseline and after the first, second, and fourth float for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration
Secondary Eating disorder severity Measured via the Eating Disorder Examination Questionnaire Obtained during the first visit
Secondary Trauma exposure Measured via the Childhood Trauma Questionnaire Obtained during the first visit
Secondary Self-ratings of changes in anxiety Measured via self-report measure (Spielberger State-Trait Anxiety Index) Obtained at baseline and immediately before and after each float session for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration
Secondary Self-ratings of anxiety sensitivity Measured via the Anxiety Sensitivity Index Obtained during the first visit
See also
  Status Clinical Trial Phase
Recruiting NCT05531604 - Appetitive Conditioning in Anorexia Nervosa
Enrolling by invitation NCT04174703 - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing N/A
Active, not recruiting NCT04883554 - Impact of an Olfactory Sensory Therapeutic Group for Adolescent Patients With Restrictive Anorexia Nervosa , Pilot Study N/A
Recruiting NCT04213820 - TMS and Body Image Treatment for Anorexia Nervosa N/A
Completed NCT03414112 - The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa Early Phase 1
Recruiting NCT06144905 - Norwegian Microbiota Study in Anorexia Nervosa
Recruiting NCT05803707 - Home-based Adapted Physical Activity in Anorexia Nervosa: a Feasibility Pilot Study N/A
Recruiting NCT05682417 - Impact of Body Schema Distortion on Remission and Weight Regain in Anorexia Nervosa N/A
Not yet recruiting NCT06380257 - Anorexia Nervosa and Brain in Adolescence
Not yet recruiting NCT04804800 - Virtual Reality Place in the Management of Body Dysmorphia Disorders in Anorexia Nervosa N/A
Not yet recruiting NCT03600610 - Evaluation of CARdiac Abnormalities by Echocardiography and MRI in Malnourished Patients Suffering From Anorexia Nervosa N/A
Completed NCT02745067 - Effectiveness of Enhanced Cognitive Behavioral Therapy (CBT-E) in the Treatment of Anorexia Nervosa N/A
Completed NCT02382055 - Changing Habits in Anorexia Nervosa: Novel Treatment Development N/A
Completed NCT03075371 - Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa N/A
Terminated NCT02240797 - Kappa Opioid Receptor Imaging in Anorexia N/A
Unknown status NCT01761942 - Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa Phase 2
Completed NCT03144986 - Insula-coil Deep TMS for Treatment Resistant Anorexia Nervosa N/A
Completed NCT01579682 - Adaptive Family Treatment for Adolescent Anorexia Nervosa N/A
Completed NCT02551445 - A fMRI Pilot Study of the Effects of Meal-support in Eating Disorders. N/A
Completed NCT00946816 - The Effects of Dietary Intervention on Gastrointestinal Function in Patients With Anorexia Nervosa and Obesity N/A